The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.a

Pulmonary embolism - Venous thrombosis/thromboembolism

Publications

Ma JY, Chuang CH

A 54-Year-Old Man With Migratory Pulmonary Consolidation and Progressive Dyspnea.

Chest. 2022;162(2):e85-e88

Mahgoub AE, Awuah D, Hussain M, Deliwala S, Bachuwa G, Younas M

Development of Venous Thromboembolism After COVID-19 mRNA-1273 Vaccine Inoculation.

Cureus. 2022;14(2):e22179

Vallone MG, Falcón AL, Castro HM, Ferraris A, Cantarella RF, Staneloni MI, Aliperti VI, Ferloni A, Mezzarobba D, Vázquez FJ, Ratti MFG

Thrombotic events following Covid-19 vaccines compared to Influenza vaccines.

European journal of internal medicine. 2022;99:82-88

Curcio R, Gandolfo V, Alcidi R, Giacomino L, Campanella T, Casarola G, Rossi R, Chiatti L, D'Abbondanza M, Commissari R, Gresele P, Pucci G, Vaudo G

Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2022;116:154-156

Tobaiqy M, MacLure K, Elkout H, Stewart D

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database.

Vaccines. 2021;9(11)

Wiest NE, Johns GS, Edwards E

A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization.

Vaccines. 2021;9(8)

Al-Maqbali JS, Al Rasbi S, Kashoub MS, Al Hinaai AM, Farhan H, Al Rawahi B, Al Alawi AM

A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.

The American journal of case reports. 2021;22:e932946

Esba LCA, Al Jeraisy M

Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST).

Expert review of vaccines. 2021;20(8):1037-1042

Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A

Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine.

Internal and emergency medicine. 2021;16(3):803-804